Structure Therapeutics Inc (GPCR)
37.76
+1.39
(+3.82%)
USD |
NASDAQ |
Nov 14, 16:00
37.05
-0.71
(-1.88%)
After-Hours: 17:27
Structure Therapeutics Research and Development Expense (Quarterly): 22.05M for June 30, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2024 | 22.05M |
| March 31, 2024 | 20.68M |
| December 31, 2023 | 20.04M |
| September 30, 2023 | 17.52M |
| June 30, 2023 | 19.41M |
| March 31, 2023 | 13.14M |
| Date | Value |
|---|---|
| December 31, 2022 | 8.36M |
| September 30, 2022 | 9.16M |
| June 30, 2022 | 10.18M |
| March 31, 2022 | 8.492M |
| December 31, 2021 | 9.907M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
8.36M
Minimum
Dec 2022
22.05M
Maximum
Jun 2024
14.45M
Average
13.14M
Median
Mar 2023
Research and Development Expense (Quarterly) Benchmarks
| Viking Therapeutics Inc | 22.78M |
| Eli Lilly and Co | 2.734B |
| Novo Nordisk AS | 1.398B |
| Pfizer Inc | 2.598B |
| Amgen Inc | 1.45B |